The Burrill Report


The Burrill Report(July 4, 2011): Comparative Effectiveness Research Brings Industry to a Defining Moment (.MP3,12.81 Mb)

Healthcare reform legislation, passed in the United States in 2010, included provisions for $1.1 billion to fund comparative effectiveness research. A new report from The Deloitte Center for Health Solutions argues that in a new value-driven healthcare system, drug and device makers will need to offer technologies that demonstrate real value to payers, providers, and patients. We spoke to Terry Hisey, vice chairman and U.S. life sciences industry leader for Deloitte, about the state of comparative effectiveness research in the United States, how it compares to other countries that have long applied measures of value to drugs and devices, and how it will force companies to think differently about the development process.

June 30, 2011
http://www.burrillreport.com/article-comparative_effectiveness_research_brings_industry_to_a_defining_moment.html